Old Web
English
Sign In
Acemap
>
Paper
>
FP13.02 Pembrolizumab + Pemetrexed-Platinum vs Pemetrexed-Platinum for Metastatic NSCLC: 4-Year Follow-up From KEYNOTE-189
FP13.02 Pembrolizumab + Pemetrexed-Platinum vs Pemetrexed-Platinum for Metastatic NSCLC: 4-Year Follow-up From KEYNOTE-189
2021
Jhanelle E. Gray
Delvys Rodriguez Abreu
Steven Francis Powell
Maximilian Hochmair
S. Gadgeel
Emilio Esteban
E. Felip
G. Speranza
F. De Angelis
Manuel Domine
S Y-S Cheng
Helge Bischoff
Nir Peled
M. Reck
Rina Hui
Edward B. Garon
Michael Boyer
Takayasu Kurata
J.C-H. Yang
E Jensen
F. Souza
M. C. Garassino
Keywords:
Internal medicine
Medicine
Platinum
Oncology
Pembrolizumab
Pemetrexed
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
7
Citations
NaN
KQI
[]